Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

December 6, 2019December 6, 2019

Therapeutic Targeting of MT1-MMP Protein May Help Halt IBD Progression, Study Suggests

News

The membrane type 1-matrix metalloproteinase (MT1-MMP) protein may be a promising therapeutic target for inflammatory bowel disease (IBD) — possibly targeting the disease in its early stages, a study ... Read more

October 22, 2019October 22, 2019

Stelara Approved in US to Treat Moderate-to-Severe Ulcerative Colitis

News

The U.S. Food and Drug Administration (FDA) has approved Stelara (ustekinumab) for the treatment of adults with ulcerative colitis (UC) that is moderately to severely active, Janssen Pharmaceuticals, Stelara’s developer ... Read more

August 23, 2019August 23, 2019

Landos Biopharma Secures $60M Financing, Continues BT-11 Development for IBD

News

Landos Biopharma’s investigational BT-11 therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is continuing testing in Phase 2 clinical trials — some of which ... Read more

July 12, 2019July 12, 2019

Th17 Immune Cells Raise Risk of Severe C. difficile in Colitis Patients, Study Shows

News

Patients with colitis are particularly susceptible to infection by the toxin-producing bacteria Clostridium difficile, but the reason remained unknown. Now, researchers have discovered that changes in the immune system, ... Read more

June 26, 2019June 26, 2019

Youngsters Diagnosed with IBD Have Increased Cancer Risk, Study Contends

News

Inflammatory bowel disease (IBD) diagnosis during childhood or adolescence may be linked with an increased risk for developing cancer, compared to the general population, according to results of a ... Read more

June 21, 2019June 21, 2019

First Patient Dosed in Phase 3 Trial of Etrasimod for Moderate to Severe UC

News

The Phase 3 trial ELEVATE UC 52 evaluating Arena Pharmaceuticals’ investigational therapy etrasimod for patients with moderately to severely active ulcerative colitis has dosed its first patient. “We are pleased ... Read more

April 17, 2019April 17, 2019

Entyvio Improves Quality of Life, Work Productivity of Ulcerative Colitis Patients, Phase 3 Study Shows

News

Treatment with Entyvio (vedolizumab), delivered into the blood or under the skin, led to significant clinical improvements and in quality of life, as well as work productivity in patients with ... Read more

March 22, 2019March 26, 2019

Ozanimod Lessens Inflammation in Crohn’s, Early Phase 2 Trial Data Show

News

Daily treatment with 1 mg of ozanimod reduced gut inflammation in patients with moderately to severely active Crohn’s disease, early data from the phase 2 STEPSTONE study show. B.G. ... Read more

March 11, 2019March 11, 2019

Plant-based Fasting-Mimicking Diet May Help Lessen IBD Severity

News

A short-term, plant-based fasting-mimicking diet followed by a normal diet lessened several of the hallmarks of inflammatory bowel disease (IBD), a study in a mouse model shows. The study, ... Read more

February 11, 2019February 11, 2019

‘Carbohydrate Monotony’ Diet May Ease IBD, Researchers Propose

News

A diet rich in multiple carbohydrate sources, including sugars, starchy carbohydrates, and dietary fiber, is a likely perpetrator of inflammatory bowel disease (IBD), two researchers believe. They say the ... Read more